Comparative Review of Depression and Anxiety Drug Coverage Across Three Formularies
How Are Major Health Plans Managing Access to Depression and Anxiety Drug Coverage?
The treatment landscape for depression and anxiety includes a broad range of established antidepressants, anxiolytics, and newer therapies with distinct indications, safety considerations, and administration requirements. As therapeutic options expand, payer strategies are becoming increasingly complex—making it more important than ever to understand how health plans structure formulary access.
In this exclusive Formulary Frontlines® report, First Report Managed Care compares formulary coverage across Blue Cross Blue Shield FEP Blue Standard, Cigna Healthcare Standard 3-Tier, and UnitedHealthcare to identify differences in tier placement, prior authorization requirements, step therapy, specialty pharmacy management, dispensing limits, and quantity limits for therapies used to treat depression and anxiety.
Key Takeaways
- Newer therapies see the greatest variation in payer coverage. Although established generic antidepressants and anxiolytics remain broadly accessible, products such as AUVELITY, SPRAVATO, and ZURZUVAE are managed differently across health plans.
- Blue Cross Blue Shield FEP provides the most consistent low-tier access with the fewest listed controls across established therapies and is the only reviewed formulary to list AUVELITY, SPRAVATO, and ZURZUVAE.
- Cigna generally places established generics on Tier 1 but commonly applies quantity limits. It provides comparatively favorable tier placement for TRINTELLIX and AUVELITY while using utilization controls such as step therapy and quantity limits.
- UnitedHealthcare applies the most intensive utilization management, frequently assigning therapies to higher tiers and using dispensing limits, quantity limits, step therapy, and prior authorization.
- Utilization management—not coverage alone—is a key differentiator. Tier placement, formulation-specific restrictions, specialty pharmacy requirements, and other controls can affect how easily patients initiate or continue treatment.
Download the full report for a comprehensive comparison of formulary positioning, utilization management strategies, and payer trends influencing access to depression and anxiety therapies.
